Broad Spectrum Chemotherapy: A Novel Approach Using Beta-Galactosidase Activated Pro-Drugs

Abstract

Gene therapy shows promise for treating prostate cancer and is being exploited in several clinical trials. A major hurdle is establishing a method of verifying transgene activity in situ. Beta-galactosidase (beta-gal) was historically the most popular reporter gene for molecular biology. I have introduced a novel concept for further exploration of gene therapy using beta- galactosidase to activate a broad-spectrum chemotherapeutic to assess the efficacy of the pro-drugs in vitro and explore growth delay in animal models. I also have developed a new beta- galactosidase molecular reporter for MRI spectra, which can be used to detection of lacZ gene expression in vivo.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Mar 01, 2007
Accession Number
ADA472114

Entities

People

  • Li Ping

Organizations

  • University of Texas at Dallas

Tags

DTIC Thesaurus Topics

  • Biology
  • Cancer
  • Cell Line
  • Chemical Shifts
  • Clinical Trials
  • Department Of Defense
  • Detection
  • Gene Expression
  • Gene Therapy
  • Molecular Biology
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Scalar Magnetometers
  • Spectra
  • Therapy
  • Tissues

Fields of Study

  • Biology

Readers

  • Medical Imaging.
  • Molecular Biology and Genetics
  • Systems Analysis and Design

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech